Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Alkermes plc Fourth Quarter 2025 Earnings Call - Alixorexton to Phase 3 as Avadel Buyout Recasts the Commercial Engine
Alkermes closed 2025 with a beefy commercial base and a strategic pivot into sleep medicine, sealing the Avadel acquisition and announcing plans to start phase 3 for alixorexton in narcolepsy this qua...
- Alkermes reported nearly $1.5 billion in total revenues for 2025, with proprietary product net sales of approximately $1.2 billion, driven by VIVITROL ($467.9M), ARISTADA ($370M), and Lybalvi ($346.7M).
- The company completed the Avadel acquisition in February 2026, using about $775 million of cash and drawing $1.525 billion of term loans due in 2031, positioning Alkermes to enter the commercial sleep medicine market.
- Alkermes expects 2026 total revenues of $1.73 billion to $1.84 billion, with proprietary product sales of $1.52 billion to $1.6 billion, reflecting roughly 10.5 months of Avadel contribution.
- +12 more takeaways
CLEAR Q4 2025 Earnings Call - CLEAR1 breakout and at least $440M Free Cash Flow guide
CLEAR closed fiscal 2025 with a clear pivot from investment to profitable scale. Q4 revenue rose 16.7% year over year to $240.8 million, bookings jumped 25.4% to $287.1 million, and Adjusted EBITDA ma...
- Q4 revenue grew 16.7% year over year to $240.8 million; Q4 Total Bookings rose 25.4% to $287.1 million.
- Full year 2025 revenue was $900.8 million, bookings $977.2 million, and Free Cash Flow totaled $343.1 million, ahead of guidance.
- Management delivered record profitability: Q4 Adjusted EBITDA of $79.9 million (33.2% margin) and full-year Adjusted EBITDA of $262.2 million (29.1% margin).
- +12 more takeaways
LivaNova PLC Q4 2025 Earnings Call - OSA PMA on Track and Epilepsy Reimbursement Jumpstarts Growth
LivaNova closed 2025 with double-digit top-line and EPS momentum, a stronger balance sheet, and a clear strategic pivot into obstructive sleep apnea. Management walked investors through steady cardiop...
- 2025 results: Double-digit revenue growth, fifth consecutive year of double-digit EPS growth, and third consecutive year of double-digit organic revenue growth.
- Q4 revenue was $361 million, up 9.5% on a constant currency and organic basis; favorable FX added about $9 million (roughly 3%).
- Cardiopulmonary Q4 revenue $207 million, full-year $785 million, up 13% year-over-year; HLM (heart-lung machine) growth remained strong (full-year mid-teens).
- +16 more takeaways
Golar LNG Limited Q4 2025 Earnings Call - On track to ~$800M EBITDA as Argentina FLNGs near start, commodity upside could dwarf base earnings
Golar spent Q4 2025 proving the plumbing of its FLNG strategy rather than selling the dream. Gimi is live and producing above contracted volumes, Hilli remains the benchmark for uptime, and Mark II co...
- Golar now owns three operational FLNG units and one Mark II conversion in progress, with a 20-year charter backlog for each of the main units.
- Gimi reached commercial operations in June 2025 and is producing above contracted volumes, invoicing a dayrate 3% above contractual levels in Q4 and showing potential for further overperformance seasonally.
- Hilli delivered 100% economic uptime in Q4, produced slightly above contracted volumes for the year, and will sail from Cameroon to Seatrium in Singapore after its current charter ends in July 2026 for life-extension and upgrades before redeployment to Argentina in mid-2027.
- +13 more takeaways
Slide Insurance Q4 2025 Earnings Call - Record Q4 as Citizens depopulation and reserve tailwinds fuel 57% GWP growth and $170M net income
Slide closed 2025 with blowout results, driven by opportunistic Citizens depopulation, strong voluntary sales and favorable prior-year reserve development. Q4 gross written premium jumped 57% to $618....
- Q4 2025 gross premiums written of $618.5 million, up 57% year-over-year, driven by Citizens depopulation and higher voluntary sales.
- Slide assumed ~152,000 policies from Citizens in the quarter, bringing policies in force to ~493,500, a 44% YoY increase.
- Net income for the quarter was $170.4 million, more than double the prior year quarter's $75.1 million; diluted EPS $1.23.
- +13 more takeaways
Lineage Fourth Quarter 2025 Earnings Call - Seasonality Returns; Guidance AFFO $2.75-$3.00, $50M Cost Cuts and $150M Development EBITDA
Lineage reported Q4 2025 results that were roughly in line with expectations, with total revenue flat year-over-year and adjusted EBITDA down 2% to $327 million. Physical occupancy showed a meaningful...
- Q4 revenue was flat year-over-year, adjusted EBITDA declined 2% to $327 million, and Q4 AFFO per share was flat at $0.83.
- Full-year 2025 adjusted EBITDA fell 2.3% to about $1.3 billion, while full-year AFFO per share rose 2.4% to $3.37, aided by better tax planning and lower maintenance capex.
- Physical same-store occupancy improved sequentially by 400 basis points to 79.3%, signaling a return to more normal seasonality and management believes inventory destocking is largely behind them.
- +12 more takeaways
Luxfer Holdings PLC Q4 2025 Earnings Call - Elektron drove earnings, guidance cautious as restructuring and timing headwinds push benefits into late 2026
Luxfer closed 2025 with modest top-line growth and cleaner earnings, led squarely by Elektron. Adjusted sales rose to $371.2 million, adjusted EBITDA to $51.9 million and adjusted EPS to $1.11, while ...
- Company posted adjusted full-year sales of $371.2 million, up 2.5% year-over-year, with adjusted EBITDA of $51.9 million, up 4.2%.
- Adjusted EPS rose 12.1% to $1.11 for 2025, reflecting operating leverage and portfolio mix shifts toward higher-margin products.
- Elektron was the clear performance engine: full-year sales of $196.4 million, up 11.6%, and adjusted EBITDA of $36.9 million, up 16%, with margins expanding toward the 20% target (full-year Elektron margin 18.8%, Q4 margin 19.6%).
- +11 more takeaways
Hippo Fourth Quarter 2025 Earnings Call - Diversified commercial growth and underwriting discipline drove profitable scale
Hippo closed 2025 with clear evidence that a shift from growth-at-all-costs to disciplined underwriting is working. The company reported over $1.1 billion of gross written premium, a 24% increase year...
- Gross Written Premium reached over $1.1 billion in 2025, up 24% year-over-year, with Q4 GWP of $288 million, up 40% YoY.
- Net Written Premium was $422 million for the year, up 13% versus 2024.
- Full-year Net Income attributable to Hippo was $58 million, or $2.22 per diluted share, a $98 million improvement year-over-year.
- +16 more takeaways
Immunocore Q4 & Full Year 2025 Earnings Call - KIMMTRAK $400M, Phase 3 Readouts Point to a Make-or-Break 2H26
Immunocore closed 2025 on commercial strength, with KIMMTRAK delivering $400 million in net revenue, up 29% year-on-year, broader global rollout and real-world duration of therapy now 14 months. Manag...
- KIMMTRAK net revenue reached $400 million in 2025, a 29% increase versus 2024.
- KIMMTRAK is approved in 39 countries and launched in 30 markets, with real-world mean duration of therapy at 14 months.
- Real-world evidence presented at ESMO IO from 150 patients showed a median overall survival of 28 months; company will publish additional U.S. RWE and 5-year registrational OS data in 2026.
- +13 more takeaways
Geron Corporation Q4 2025 Earnings Call - RYTELO set to scale in 2026 with $220M-$240M guidance targeting ~8,000 second-line lower-risk MDS patients
Geron closed 2025 with a full commercial year behind RYTELO and is explicitly repositioning as a U.S.-focused hematology commercial story in 2026. Q4 net revenue was $48 million and full-year RYTELO s...
- RYTELO net revenue: Q4 2025 was $48 million; full-year 2025 RYTELO net revenue totaled $184 million (vs $76M in 2024).
- 2026 guidance: RYTELO net revenue of $220M to $240M; total operating expenses guided to $230M to $240M, implying roughly $20M YoY reduction at the midpoint. Management expects a back-half-weighted growth cadence in 2026.
- Commercial focus: Geron is prioritizing second-line, lower-risk MDS patients in the U.S., estimating an addressable population of approximately 8,000 patients. Second-line is the primary growth lever.
- +11 more takeaways